AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17181846
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered pre- and postoperatively
Trial: 11772245
Drug: Psychopharmacological agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychopharmacological agents
Trial: 11772245
Drug: Alternative therapies
RxNorm normalized name: HERBS/ALTERNATIVE THERAPIES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative therapies (homeopathy, acupuncture, special diets, herbal medication, psychological treatments, hypnotherapy)
Trial: 7974334
Drug: Weight adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight adjusted dose of Fragmin (100 IU/kg) subcutaneously twice a day for 10 days (group A)
Trial: 7974334
Drug: Dosage based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage based on anti factor Xa assay to obtain a target concentration of 0.5 to 1 IU/ml (group B)
Trial: 2690622
Drug: Ofloxacin 300
RxNorm normalized name: ofloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 300 mg given twice daily
Trial: 2690622
Drug: Carbenicillin 764
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin 764 mg given every six hours
Trial: 2690622
Drug: Trimethoprim/sulfamethoxazole combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole combination
Trial: 24916134
Drug: Albuterol (A)
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (A)
Trial: 24916134
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of magnesium sulfate and albuterol (M + A)
Trial: 23454551
Drug: CBT (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT (Cognitive and Behavioural Therapy) for 6 months
Trial: 21300930
Drug: AC→T (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC→T (sequential doxorubicin and cyclophosphamide followed by docetaxel)
Trial: 21300930
Drug: TAC (concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (concurrent doxorubicin, cyclophosphamide, and docetaxel)
Trial: 21300930
Drug: Treatment arm,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm, time point, age, and tamoxifen use
Trial: 2946604
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (Diane, 2 mg)
Trial: 2946604
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (Androcur, 100 mg)
Trial: 31169293
Drug: MF59-adjuvanted inactivated
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted inactivated A(H7N9) vaccine
Trial: 31169293
Drug: AS03-adjuvanted inactivated
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted inactivated A(H7N9) vaccine
Trial: 9807036
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 500 mg twice daily
Trial: 2509103
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional therapy without acute catheterization)
Trial: 30353600
Drug: Accelerated transition
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated transition from oncological treatment to home-based specialized palliative care (SPC) and dyadic psychological support
Trial: 27809351
Drug: Memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (20 mg/day) plus sertraline (200 mg/day)
Trial: 27809351
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus sertraline (200 mg/day)
Trial: 19863279
Drug: Adenosine inhalation
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine inhalation challenge
Trial: 7961321
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation challenge
Trial: 20509997
Drug: Entecavir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir (0.5 mg once daily for 48 weeks)
Trial: 17302253
Drug: Lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (100 mg once daily for 48 weeks)
Trial: 14966092
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m(2) plus carboplatin AUC6
Trial: 14966092
Drug: Paclitaxel 225
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 225 mg/m(2) plus carboplatin AUC6
Trial: 9135312
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 0.5 ml (25 micrograms)
Trial: 9135312
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.5 ml (control group)
Trial: 9135312
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 0.5% 2 ml
Trial: 6784976
Drug: Bromocriptine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 7.5 mg daily
Trial: 28418102
Drug: solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solifenacin 5 mg
Trial: 27607187
Drug: darifenacin 7.5
RxNorm normalized name: darifenacin 7.5 MG
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: darifenacin 7.5 mg
Trial: 20107867
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with 0.5 ml preservative-free 1% intracameral lidocaine (2 drops of proxymethacaine 0.5%)
Trial: 20107867
Drug: Subtenon anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtenon anaesthesia with 4 ml 2% lignocaine
Trial: 19441669
Drug: peg‐IFNalpha2a (n=18)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg‐IFNalpha2a (n=18) or peg‐IFNalpha2b (n=8) plus RBV in standard doses
Trial: 16025959
Drug: Modified Sanjiasan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Sanjiasan decoction (MSD), one dosage each day for three months.
Trial: 16025959
Drug: Naofukang 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naofukang 0.8 g three times a day for three months (Control).
Trial: 1714951
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 day 1; Bleomycin 15 mg IV day 1, and 16 mg/m2/d CI days 1 to 5; Fluorouracil 650 mg/m2/d CI days 1 to 5 (PBF)
Trial: 6172999
Drug: Morphine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (1 mg . kg‐1, iv at 100 micrograms . kg‐1 . min‐1)
Trial: 27759463
Drug: Ixekizumab Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab Q2W (80 mg every two weeks after a 160 mg starting dose)
Trial: 27759463
Drug: Ixekizumab Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab Q4W (80 mg every four weeks after a 160 mg starting dose)
Trial: 27759463
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg bi-weekly)
Trial: 22096031
Drug: High ST2
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ST2 concentrations (>35 μg/L)
Trial: 18815445
Drug: Direct-current cardioversion
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-current cardioversion (DCC) vs Pharmacological treatment
Trial: 17206078
Drug: Bravo capsule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bravo capsule
Trial: 15991867
Drug: Intramuscular botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular botulinum toxin A (BTX‐A)
Trial: 15991867
Drug: Structured rehabilitation
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured rehabilitation (physiotherapy and occupational therapy three times a week for 6 months)
Trial: 8560678
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg daily bicalutamide
Trial: 8560678
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg daily bicalutamide
Trial: 8560678
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg bicalutamide
Trial: 1883258
Drug: High-dose right
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose right unilateral electroconvulsive therapy (378-mC charge)
Trial: 1883258
Drug: Bilateral electroconvulsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral electroconvulsive therapy
Trial: 30767156
Drug: Immersive Virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive Virtual Reality Environment (VRE) with Cognitive Behaviour Therapy (CBT); 1 session introducing CBT techniques and 4 VRE sessions
Trial: 30767156
Drug: Immersive Virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive Virtual Reality Environment (VRE) with Cognitive Behaviour Therapy (CBT)
Trial: 26771522
Drug: Perindopril 5
RxNorm normalized name: amlodipine-perindopril 5 mg-7 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 5 mg/Amlodipine 5 mg (Per/Amlo group)
Trial: 26771522
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg (Amlo group)
Trial: 26771522
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg (Per group)
Trial: 22785114
Drug: ramipril +
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ramipril + high‐dose rapamycin (trough level 6‐8 ng/mL)
Trial: 22785114
Drug: ramipril +
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ramipril + low‐dose rapamycin (trough levels 2‐4 ng/mL)
Trial: 20188315
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy in combination with exercise training
Trial: 11923049
Drug: Prostacyclin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin plus conventional therapy
Trial: 10438381
Drug: Efavirenz, 600
RxNorm normalized name: Efavirenz, 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz, 600 mg daily
Trial: 29989171
Drug: Antioxidant (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant (500 mg l-ascorbic acid and 450 IU dl-α-tocopherol acetate, 2 capsules/day for 8 weeks)
Trial: 29989171
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose capsules of identical appearance)
Trial: 25266929
Drug: 5-week Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-week Internet-based guided self-help program based on exposure therapy with weekly student support
Trial: 17699476
Drug: C.E.R.A. once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. once monthly
Trial: 17699476
Drug: C.E.R.A. twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. twice monthly
Trial: 15073671
Drug: Full-dose ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose ganciclovir (5 mg/kg intravenously [iv] twice daily)
Trial: 15073671
Drug: Half-dose ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose ganciclovir (5 mg/kg iv once daily) plus half-dose foscarnet (90 mg/kg iv once daily)
Trial: 9669786
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (n = 586)
Trial: 9669786
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n = 582)
Trial: 17427
Drug: Pancuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.08 mg/kg
Trial: 2899988
Drug: Vecuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.08 mg/kg
Trial: 3242978
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of histamine and PGD2
Trial: 21681697
Drug: Intralesional 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional 5-Fluorouracil combined with topical silicone
Trial: 21681697
Drug: Perilesional surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perilesional surgical excision of keloids combined with topical silicone
Trial: 18505169
Drug: CD4+ T-cell
RxNorm normalized name: Autologous CD4+CD25hiFoxP3+regulatory T cells
DrugBank: Autologous CD4+CD25hiFoxP3+regulatory T cells (DB18655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4+ T-cell count-guided use of ART (Drug Conservation arm; DC)
Trial: 16783561
Drug: Clarithromycin 800
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 800 mg daily for 6 days
Trial: 16783561
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg daily for 6 days
Trial: 14666027
Drug: N-acetylcysteine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime followed by infusion at 20 mg.kg(‐1).h(‐1), n = 20)
Trial: 10844878
Drug: Orthodox treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodox treatment (Version A)
Trial: 10844878
Drug: Unconventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unconventional treatment (Version B)
Trial: 1739873
Drug: Calcitonin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day)
Trial: 1739873
Drug: Calcitonin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day) + Phosphate (750 mg/day)
Trial: 1739873
Drug: Calcitonin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day) + Norandrostenolone decanoate (50 mg/month)
Trial: 18565275
Drug: l-tetrahydropalmatine (l-THP)
RxNorm normalized name: Tetrahydropalmatine
DrugBank: Tetrahydropalmatine (DB12093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-tetrahydropalmatine (l-THP)
Trial: 2686340
Drug: Enisoprost (prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enisoprost (prostaglandin E1 analogue) at doses of 10, 25, 50, 100, 200, or 400 micrograms
Trial: 792865
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate (ointment)
Trial: 22253016
Drug: Oral-sparing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-sparing group (OR-SP), n = 24
Trial: 22253016
Drug: Oral-unsparing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-unsparing group (OR-USP), n = 24
Trial: 22253016
Drug: Oral-sparing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-sparing group (OR-SP)
Trial: 22253016
Drug: Oral-unsparing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-unsparing group (OR-USP)
Trial: 20551644
Drug: FeSO(4) gel
RxNorm normalized name: FESO
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FeSO(4) gel (1 mmol/l FeSO(4))
Trial: 20551644
Drug: F gel
RxNorm normalized name: APF Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F gel (NaF 1.23%)
Trial: 20551644
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (negative control)
Trial: 10978853
Drug: HMB supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB supplementation (3.0 g HMB/d)
Trial: 30716550
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (home-based EHS plus 10 weekly books)
Trial: 30121640
Drug: 5-FU continuous
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU continuous infusion
Trial: 24780501
Drug: CER-001 3
RxNorm normalized name: CER-001
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER-001 3 mg/kg
Trial: 24780501
Drug: CER-001 6
RxNorm normalized name: CER-001
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER-001 6 mg/kg
Trial: 24780501
Drug: CER-001 12
RxNorm normalized name: CER-001
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER-001 12 mg/kg
Trial: 22836250
Drug: Hydrocortisone and
RxNorm normalized name: hydrocortisone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone and Yohimbine (combined administration)
Trial: 20308693
Drug: Caffeine (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4.5 mg/kg)
Trial: 17902094
Drug: High oral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oral carbohydrate (CHO) beverage (125 mg/ml)
Trial: 17902094
Drug: Low oral
RxNorm normalized name: Milkflow oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low oral carbohydrate (CHO) beverage (25 mg/ml)
Trial: 16096241
Drug: Vocational training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocational training programme plus psychosomatic treatment
Trial: 11911556
Drug: Sprinkle-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprinkle-dose regimen of 60-mg MSER capsule on applesauce
Trial: 11911556
Drug: Intact 60-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact 60-mg MSER capsule swallowed whole
Trial: 26612407
Drug: EAS regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAS regimen (esomeprazole 20 mg b.i.d., amoxicillin 500 mg q.i.d., sitafloxacin 100 mg b.i.d.)
Trial: 26612407
Drug: EMS regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMS regimen (esomeprazole 20 mg b.i.d., metronidazole 250 mg b.i.d., sitafloxacin 100 mg b.i.d.)
Trial: 23550916
Drug: Both adjunctive
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both adjunctive FC therapies
Trial: 18412989
Drug: Markers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Markers of bone turnover (e.g., serum bone alkaline phosphatase, total osteocalcin, procollagen type I N-terminal propeptide)
Trial: 18412989
Drug: Antiresorptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive therapy (e.g., hormone-replacement therapy, raloxifene, bisphosphonates)
Trial: 20064989
Drug: Sodium dichloroisocyanurate
RxNorm normalized name: Sodium dichloroisocyanurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium dichloroisocyanurate (NaDCC) tablets
Trial: 16263979
Drug: Sublingual sugar
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual sugar administration (SG) - 2.5 g of sugar under the tongue, with subgroups of 0.1 g/kg, 0.15 g/kg, and 0.2 g/kg
Trial: 16263979
Drug: Intravenous dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextrose administration (IG) - 8 mL of 30% dextrose in a single bolus
Trial: 16263979
Drug: Oral sugar
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sugar administration (OG) - 2.5 g of sugar
Trial: 16263979
Drug: Water administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water administration (C)
Trial: 9536540
Drug: 2% fusidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% fusidic acid lotion (Fucidin lotion)
Trial: 7906472
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% timolol
Trial: 3300313
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg orally twice daily)
Trial: 11837758
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose glucocorticoid pulse therapy (GPT)
Trial: 11837758
Drug: No glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No glucocorticoid pulse therapy (Control)
Trial: 31481504
Drug: Rituximab (R)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (R) at 375 mg/m2 weekly for 4 weeks and Ipilimumab (I) at 3 mg/kg on day 1 and every 3 weeks for four doses